Best of Precision Oncology 2021

bookLearning Objectives

Chaired by Prof. Solange Peters and Dr. Adrian Sacher, along with international speakers, this NEW flagship event will profile key foundational topics as well as emerging strategies associated with precision oncology. Attendees will be able to optimize diagnosis, treatment selection, and evidence-based management of patients with cancer using emerging diagnostic technologies to personalize and tailor therapies.
Key content areas include: 
  • State of the art tools for early detection of disease & monitoring of molecularly targeted therapies 
  • Precision oncology biomarkers to guide therapeutic decision making 
  • Novel precision therapies and understanding the treatment pathways to guide new therapies 
The event will offer specific insights on precision oncology advances in key tumor areas including breast cancer, hematology, gastrointestinal cancer, genitourinary cancer, lung cancer, melanoma.  



Friday, October 15, 2021

Local Time

  • Timezone: America/New_York
  • Date: Friday, October 15, 2021
  • Time: 9:00 am - 2:20 pm


Registration is now closed. If you would like to attend and have yet to register, please contact with the subject line: Best of Precision Oncology – Late Registration Request

Scientific Agenda

9:00 am – 9:45 am EDT

Eli Lilly Breakfast Symposium: Assessing RET-Altered Tumors: An Increasingly Important Target for Precision Oncology – Dr. Alex Drilon with panelist, Dr. Diana Ionescu

9:45 am – 10:00 am EDT

Welcome Address by Chairs – Dr. Adrian Sacher & Prof. Solange Peters

10:00 am – 10:30 am EDT

Molecular Testing – What practicing clinicians need to know – Dr. Ming Tsao

10:30 a.m. – 11:00 a.m. EDT

Tumour Agnostic Biomarker Driven Therapy – Dr. Barbara Melosky

11:00 am – 11:15 am EDT


11:15 am – 11:55 am EDT

Breakout Sessions

  • Hematology – Dr. Aaron Schimmer with Prof. Gabriela Baerlocher
  • Lung Cancer – Dr. Roy Herbst with Dr. Natasha Leighl
  • Breast Cancer – Prof. Matteo Lambertini with Prof. Samreen Ahmed
  • Melanoma – Prof. Teresa Amaral with Prof. John Haanen
  • GU – Prof. Thomas Powles with Dr. Daniel Heng
  • GI – Dr. Daniel Renouf with Prof. Elizabeth Smyth

11:55 am – 12:25 pm EDT

Lunch Break

12:25 pm – 1:10 pm EDT

Pfizer Lunch Symposium: Access to Biomarker Testing in Canada: Clinician and Patient Viewpoints – Dr. Rachel Goodwin with panelists, Dr. Brandon Sheffield and Barry Stein

1:10 pm – 1:40 pm EDT

Debate: Be it resolved that precision therapies should only be adopted based on the results of randomized Phase 3 Trials – Dr. Jack West vs. Dr. Christian Rolfo

1:40 pm – 2:10 pm EDT

Keynote Lecture – Future Look at Emerging Technology and Targets in Oncology – Prof. Tony Mok

2:10 pm – 2:20 pm EDT

Closing Remarks by Chairs – Dr. Adrian Sacher & Prof. Solange Peters

personAbout the Faculty

Dr. Adrian Sacher

Dr. Adrian Sacher 

Conference Chair

Dr. Sacher is a staff medical oncologist at Princess Margaret Hospital and an assistant professor in the Departments ofMedicine& Immunology at the University of Toronto. Dr. Sacher completed his medical degree at the University of Toronto and residency at the Toronto General Hospital and Princess Margaret Cancer Center. He has previously completed a fellowship in thoracic oncology at the Dana-Farber Cancer Institute and holds a master’s degree in clinical trial design, genomics, and drug development from Harvard Medical School.

Dr. Sacher’sresearch focuses on novel immunotherapeutics including immune checkpoint inhibitors, immune agonists, personalized vaccines, epigenetic therapy, direct KRAS inhibitors, and adoptive cell therapy. He is primarily interested in understanding the mechanisms of primary and acquired resistance to immunotherapy and developing tissue and blood-based biomarkers as well as humanized animal models to better understand the biology of anti-tumor immune responses. He has a particular interest in the immunobiology of KRAS mutant tumors and therapeutic strategies to address oncogene-addicted cancers. He has significant previous translational research experience in both tissue genomics and the development of blood-based biomarkers including plasma genotyping.

Solange Peters

Prof. Solange Peters

Conference Chair

Solange Peters, MD, PhD, is a full professor and chair of medical oncology, as well as the thoracic malignancies program in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Prof. Peters has specialized in thoracic tumors, lung cancer, and pleural tumors. Prof. Peters is currently in charge of teaching and patient care in thoracic malignancies at Lausanne University, where she is building a translational program in collaboration with the Swiss Federal Institute of Technology and the Ludwig Institute. Her main fields of interest are new biomarkers discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy. Her current research projects are mainly focused on innovative immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator and Foundation Council member of the European Thoracic Oncology Platform. Professor Peters has authored numerous peer-reviewed manuscripts and book chapters, acts as associate editor of the Annals of Oncology, serves on the editorial board of several other oncology journals, and was the deputy editor of the Journal of Thoracic Oncology for 10 years. Prof. Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) – where she created the Women for Oncology Committee and for which she is the youngest President ever for an extended time of 3 years 2020-2022, and the International Association for the Study of Lung Cancer (IASLC) – were she was a previous Board of Directors member.


For sponsorship-related inquiries, please contact Bernadette Gregoris at

Platinum Sponsors

Amgen Oncology
Bristol Myers Squibb logo
AstraZeneca logo
Bristol Myers Squibb logo
Lilly logo

Silver Sponsors

Exact Sciences logo
Merck logo
Roche logo
Ipsen logo

Bronze Sponsors